» Articles » PMID: 27114277

Small-Molecule Inhibitors Targeting Topoisomerase I As Novel Antituberculosis Agents

Abstract

Bacterial topoisomerase functions are required for regulation of DNA supercoiling and overcoming the DNA topological barriers that are encountered during many vital cellular processes. DNA gyrase and topoisomerase IV of the type IIA bacterial topoisomerase family are important clinical targets for antibacterial therapy. Topoisomerase I, belonging to the type IA topoisomerase family, has recently been validated as a potential antitubercular target. The topoisomerase I activity has been shown to be essential for bacterial viability and infection in a murine model of tuberculosis. Mixture-based combinatorial libraries were screened in this study to identify novel bacterial topoisomerase I inhibitors. Using positional-scanning deconvolution, selective small-molecule inhibitors of bacterial topoisomerase I were identified starting from a polyamine scaffold. Antibacterial assays demonstrated that four of these small-molecule inhibitors of bacterial topoisomerase I are bactericidal against Mycobacterium smegmatis and Mycobacterium tuberculosis The MICs for growth inhibition of M. smegmatis increased with overexpression of recombinant M. tuberculosis topoisomerase I, consistent with inhibition of intracellular topoisomerase I activity being involved in the antimycobacterial mode of action.

Citing Articles

: Pathogenesis and therapeutic targets.

Yang J, Zhang L, Qiao W, Luo Y MedComm (2020). 2023; 4(5):e353.

PMID: 37674971 PMC: 10477518. DOI: 10.1002/mco2.353.


A CcdB toxin-derived peptide acts as a broad-spectrum antibacterial therapeutic in infected mice.

Bhowmick J, Nag M, Ghosh P, Rajmani R, Chatterjee R, Karmakar K EMBO Rep. 2023; 24(7):e55338.

PMID: 37166011 PMC: 10328072. DOI: 10.15252/embr.202255338.


Unraveling topoisomerase IA gate dynamics in presence of PPEF and its preclinical evaluation against multidrug-resistant pathogens.

Maurya V, Singh R, Singh R, Pandey S, Yadav P, Parashar P Commun Biol. 2023; 6(1):195.

PMID: 36807602 PMC: 9938908. DOI: 10.1038/s42003-023-04412-1.


Localization of topoisomerase I C-terminal sequence motif required for inhibition by endogenous toxin MazF4.

Garcia P, Borrero R, Annamalai T, Diaz E, Balarezo S, Tiwari P Front Microbiol. 2022; 13:1032320.

PMID: 36545199 PMC: 9760754. DOI: 10.3389/fmicb.2022.1032320.


Implementation of a mycobacterial CRISPRi platform in Mycobacterium abscessus and demonstration of the essentiality of ftsZ.

Gupta R, Rohde K Tuberculosis (Edinb). 2022; 138:102292.

PMID: 36495774 PMC: 11552333. DOI: 10.1016/j.tube.2022.102292.


References
1.
Houghten R, Pinilla C, Appel J, Blondelle S, Dooley C, Eichler J . Mixture-based synthetic combinatorial libraries. J Med Chem. 1999; 42(19):3743-78. DOI: 10.1021/jm990174v. View

2.
Garcia M, Blazquez M, Ferrandiz M, Sanz M, Silva-Martin N, Hermoso J . New alkaloid antibiotics that target the DNA topoisomerase I of Streptococcus pneumoniae. J Biol Chem. 2010; 286(8):6402-13. PMC: 3057782. DOI: 10.1074/jbc.M110.148148. View

3.
Tang S, Shapiro T . Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes. Antimicrob Agents Chemother. 2009; 54(2):620-6. PMC: 2812133. DOI: 10.1128/AAC.01025-09. View

4.
Yamaguchi Y, Inouye M . An endogenous protein inhibitor, YjhX (TopAI), for topoisomerase I from Escherichia coli. Nucleic Acids Res. 2015; 43(21):10387-96. PMC: 4666372. DOI: 10.1093/nar/gkv1197. View

5.
Weinreich M, Yigit H, Reznikoff W . Overexpression of the Tn5 transposase in Escherichia coli results in filamentation, aberrant nucleoid segregation, and cell death: analysis of E. coli and transposase suppressor mutations. J Bacteriol. 1994; 176(17):5494-504. PMC: 196738. DOI: 10.1128/jb.176.17.5494-5504.1994. View